{
    "nctId": "NCT01695057",
    "briefTitle": "Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer",
    "officialTitle": "A Pilot Clinical Trial to Evaluate the Biological Activity of HDAC (Histone Deacetylase Transferases) Inhibition on ER and PR Expression in Triple Negative Invasive Breast Cancer",
    "overallStatus": "WITHDRAWN",
    "conditions": "Stage II Breast Cancer, Stage IIIA Breast Cancer, Triple-negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Combined PR/ER response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Resectable tumor measuring 2cm or more\n* Histologically documented, newly diagnosed, triple negative invasive breast cancer characterized by 0% immunohistochemistry (IHC) nuclear staining for ER-alpha, 0% IHC nuclear staining for PR-alpha, and no amplification of human epidermal growth factor receptor 2 (HER2)/neu by fluorescent in situ hybridization (FISH) using institutional standard; standard IHC assays for ER and PR use antibodies to ER-alpha and PR-alpha and PR-beta\n* Southwest Oncology Group (SWOG) performance status of less than or equal to 1\n* Absolute neutrophil count (ANC) \\>= 1500/uL\n* Hemoglobin (Hgb) \\>= 9 g/dL\n* Platelets \\>= 100,000/uL\n* Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic pyruvate transaminase (SGPT) =\\< 2.5 x upper limit of normal (ULN) or =\\< 5.0 x ULN in patients with liver metastases\n* Creatinine =\\< 2.0 mg/dL or calculated creatinine clearance \\>= 50 ml/min\n* Albumin \\>= 3 g/dL\n* Potassium \\>= lower limit normal (LLN)\n* Phosphorous \\>= LLN\n* Calcium \\>= LLN\n* Magnesium \\> LLN\n* Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to start of treatment\n* Accessible for treatment and follow-up\n* Written informed consent prior to study entry\n\nExclusion Criteria:\n\n* HER2/neu amplification by FISH\n* Concurrent neoadjuvant anti-cancer treatment with chemotherapy, endocrine therapy, biologically targeted therapy or radiotherapy\n* Known hypersensitivity to SAHA\n* Preexisting hepatic impairment or renal impairment\n* Intent to receive additional neoadjuvant therapy prior to surgery\n* Concurrent use of an HDAC inhibitor or hydralazine\n* Known diagnosis of human immunodeficiency virus (HIV) infection\n* Major surgery \\< 4 weeks prior to starting study drug\n* Pregnant or breastfeeding or female of reproductive potential not using an effective method of birth control\n* Other concurrent severe, uncontrolled infection or intercurrent illness, including but not limited to ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements\n* Prior antiestrogens (selective estrogen receptor modulator \\[SERM\\] or aromatase inhibitors) within 6 months of study entry\n* Underlying medical, psychiatric or social conditions that would preclude patient from receiving treatment",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}